Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
20.61
USD
|
-0.39%
|
|
-2.65%
|
+43.32%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
623.1
|
2,157
|
931.8
|
847.2
|
1,068
|
1,570
|
-
|
-
|
Enterprise Value (EV)
1 |
393.7
|
1,838
|
841.1
|
804.5
|
1,068
|
1,200
|
1,570
|
1,570
|
P/E ratio
|
-9.11
x
|
-19.3
x
|
-7.11
x
|
-6.11
x
|
-6.91
x
|
-8.12
x
|
-7.91
x
|
-9.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
127
x
|
15.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
127
x
|
15.8
x
|
EV / EBITDA
|
-5.83
x
|
-20
x
|
-6.44
x
|
-5.78
x
|
-6.47
x
|
-5.17
x
|
-6.28
x
|
-4.81
x
|
EV / FCF
|
-7.19
x
|
-25.5
x
|
-7.96
x
|
-7.27
x
|
-8.54
x
|
-6.15
x
|
-7.77
x
|
-9.42
x
|
FCF Yield
|
-13.9%
|
-3.92%
|
-12.6%
|
-13.8%
|
-11.7%
|
-16.2%
|
-12.9%
|
-10.6%
|
Price to Book
|
2.64
x
|
2.84
x
|
1.83
x
|
1.98
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,315
|
66,035
|
66,556
|
68,264
|
74,272
|
76,181
|
-
|
-
|
Reference price
2 |
13.75
|
32.66
|
14.00
|
12.41
|
14.38
|
20.61
|
20.61
|
20.61
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
12.37
|
99.08
|
EBITDA
1 |
-67.48
|
-91.9
|
-130.7
|
-139.1
|
-165
|
-232.3
|
-250
|
-326.7
|
EBIT
1 |
-67.48
|
-91.9
|
-131.3
|
-139.9
|
-165.8
|
-230.6
|
-246.5
|
-197.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,992.91%
|
-199.08%
|
Earnings before Tax (EBT)
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-217.4
|
-241.9
|
-196.5
|
Net income
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-216.7
|
-236.1
|
-202.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,909.15%
|
-204.68%
|
EPS
2 |
-1.510
|
-1.690
|
-1.970
|
-2.030
|
-2.080
|
-2.538
|
-2.607
|
-2.114
|
Free Cash Flow
1 |
-54.76
|
-72
|
-105.7
|
-110.7
|
-125
|
-195
|
-202
|
-166.8
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,633.15%
|
-168.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-41.37
|
-32.87
|
-32.6
|
-35.15
|
-36.4
|
-34.95
|
-36.36
|
-39.79
|
-42.26
|
-46.55
|
-54.22
|
-55.3
|
-56.1
|
-57.3
|
-
|
-
|
EBIT
1 |
-
|
-33.04
|
-32.78
|
-35.33
|
-36.59
|
-35.16
|
-36.57
|
-40
|
-42.47
|
-46.76
|
-54.45
|
-56.41
|
-58.61
|
-61.09
|
-56.6
|
-58.35
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-49.52
|
-53.68
|
-55.86
|
-58.3
|
-59.15
|
-60.4
|
Net income
1 |
-
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-49.52
|
-53.56
|
-55.78
|
-57.81
|
-57.1
|
-58.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.4900
|
-0.4900
|
-0.5200
|
-0.5300
|
-0.4900
|
-0.5000
|
-0.5300
|
-0.5000
|
-0.5500
|
-0.5900
|
-0.6292
|
-0.6517
|
-0.6664
|
-0.6625
|
-0.6800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
2/24/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/23/23
|
5/10/23
|
8/3/23
|
11/2/23
|
2/27/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
229
|
318
|
90.7
|
42.6
|
-
|
370
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-54.8
|
-72
|
-106
|
-111
|
-125
|
-195
|
-202
|
-167
|
ROE (net income / shareholders' equity)
|
-33.3%
|
-21.6%
|
-23.3%
|
-29.3%
|
-37.3%
|
-60%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
212.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.220
|
11.50
|
7.640
|
6.270
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-1.310
|
-1.320
|
-1.580
|
-1.640
|
-1.610
|
-2.540
|
-2.100
|
1.550
|
Capex
1 |
-
|
2.17
|
1.15
|
0.63
|
0.17
|
1.13
|
1.9
|
1.9
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
15.36%
|
1.92%
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
20.61
USD Average target price
30.25
USD Spread / Average Target +46.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.32% | 1.57B | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|